WAVEMAN · COMPANY

PRCT · Procept Biorobotics Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

PRCT

Name: PROCEPT BioRobotics Corp (PRCT) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

PROCEPT BioRobotics Corp

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001588978

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$2.6M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

142

13F, latest reported quarter

REVENUE GROWTH

+37.2%

XBRL, annual

NET MARGIN

-31.0%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$2.6M over 180 days

+$469.8K over 90 days

more than 96% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

142 funds added or opened last quarter

more than 66% of Medical Devices

REVENUE

+37.2% year over year

more than 87% of Medical Devices

MARGIN

-31.0% net margin

below 66% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

142 funds added or opened positions in the latest 13F quarter, of 256 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -44.5%

-44.5%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $2.6M bought by insiders over 180 days, 142 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, PROCEPT BioRobotics Corp insiders bought a net $2.6M of stock across 184 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Wood Larry L

President, CEO

BUY

2026-08-07

23,900.0

$498.3K

Nouri Alaleh

EVP, CLO, CORP. SEC.

SELL

2026-06-08

285.0

$8.1K

Waters Kevin

EVP, CFO

SELL

2026-06-08

357.0

$10.2K

Templin Barry L

EVP, Chief Technology Officer

SELL

2026-06-08

358.0

$10.2K

Nouri Alaleh

EVP, CLO, CORP. SEC.

SELL

2026-03-19

3,031.0

$78.3K

184 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 179 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

4,869,828.0 sh

$110.0M

BNP PARIBAS ASSET MANAGEMENT Holding S.A.

2,823,849.0 sh

$63.8M

VANGUARD PORTFOLIO MANAGEMENT LLC

2,526,802.0 sh

$57.1M

VANGUARD CAPITAL MANAGEMENT LLC

2,460,802.0 sh

$55.6M

Chicago Capital, LLC

2,073,237.0 sh

$46.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

EVOLUTIONARY TREE INNOVATORS FUND

$486.7K POSITION · AS OF 2026-02-28

2.4%

Taylor Frigon Core Growth Fund

$591.6K POSITION · AS OF 2026-02-28

2.0%

AlphaCentric Robotics and Automation Fund

$375.1K POSITION · AS OF 2026-03-31

1.7%

State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF

$2.1M POSITION · AS OF 2026-03-31

1.6%

Global X HealthTech ETF

$489.9K POSITION · AS OF 2026-02-28

1.4%

Wasatch Ultra Growth Fund

$5.4M POSITION · AS OF 2026-03-31

1.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 6 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

3 ACTIVE

What changed recently

PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

2026-09-03 · Active Not Recruiting → Unknown

Not applicable

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$308.1M	$224.5M	$136.2M	$75.0M
GROSS PROFIT	$196.2M	$137.1M	$71.0M	$37.1M
OPERATING INCOME	$-103.9M	$-96.6M	$-109.2M	$-80.7M
NET INCOME	$-95.6K	$-91.4K	$-105.9K	$-87.2K
EPS (DILUTED)	-1.72	-1.75	-2.24	-1.96
OPERATING CASH FLOW	$-49.0M	$-99.2M	$-108.0M	$-80.4M
CASH	$286.5M	$333.7M	$257.2M	$221.9M
LONG-TERM DEBT	$51.6M	$51.5M	$51.3M	$51.2M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE